4th Quarter - Amendment

COVIDIEN LP for COVIDIEN LP

Firm
Client
Income
—
Expenses
$490,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 18, 2013 $470,000 Replaced
4th Quarter - Amendment (this page) Jul 19, 2013 $490,000 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S.23/H.R.1249: America Invents Act (all provisions).

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
WHITNEY GARDINER —
JOHN CHRISTOPHER KALAVRITINOS —
TIMOTHY MCBRIDE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); U.S. Trade Representative (USTR)

Bills named: S. 23 (112th), H.R. 1249 (112th)

Trade (domestic/foreign) TRD

Free Trade Agreement; HR 3078: United State Columbia Trade Promotion Agreement (All provisions relevant to medical device companies, in particular the device-specific provisions listed in the US-Korea Free Trade Agreement); HR 3079: United States Panama Trade Promotion Agreement (All provisions relevant to medical device companies, in particular the device-specific provisions listed in the US-Korea Free Trade Agreement)HR 3080: United States - Korea Free Trade Agreement (All provisions relevant to medical device companies, in particular the device-specific provisions listed in the US-Korea Free Trade Agreement)

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
WHITNEY GARDINER —
JOHN CHRISTOPHER KALAVRITINOS —
TIMOTHY MCBRIDE —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 3079 (112th), H.R. 3080 (112th), H.R. 3078 (112th)

Taxation/Internal Revenue Code TAX

International tax on foreign direct investment generally; Corporate Tax Reform generally; S.1346: Stop Tax Haven Abuse Act (all provisions); H.R. 62: International Tax Competitiveness Act of 2011 (all provisions).

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
WHITNEY GARDINER —
TIMOTHY MCBRIDE —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); U.S. Trade Representative (USTR); SENATE

Bills named: S. 1346 (112th), H.R. 62 (112th)

Health Issues HCR

General issues related to FDA device approval process; issues related to Patient Protection and Affordable Care Act Implementation (Accountable Care Organization, Medical Device Tax); S.17/S.262/H.R.436/H.R.488/H.R.734: Medical Device Access and Innovation Protection Act (all provisions); HEU/LEU related issues for Nuclear Medicine. S.99: American Medical Isotopes Production Act (all provisions).H.R. 3209: Premarket Predictability Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3203: Novel Device Regulatory Relief Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3230: Keeping America Competitive Through Harmonization Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3205: FDA Renewing Efficiency from Outside Review Management Act. (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3211: Humanitarian Device Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3208: Patients Come First Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3206: Cultivating Scientific Experts to Foster Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3214: Food and Drug Administration Mission Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3204: Guidance Accountability and Transparency Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1700: The Medical Device Regulatory Improvement Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1865: The Patient Access to Medical Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1943: Novel Device Regulatory Relief Act of 2011(All provisions related to the FDA and the regulation of medical devices generally); S. 1972: A bill to amend the Food and Drug Administrations mission (All provisions related to the FDA and the regulation of medical devices generally); S. 1995: A bill to enhance Food and Drug Administration oversight of medical device recalls, to provide for the conditional clearance of certain medical devices, and for other purposes (All provisions related to the FDA and the regulation of medical devices generally); S.3187: Food and Drug Administration Safety and Innovation Act as well as Amendment 2151 on reclassification of hydrocodone sponsored by Senator Manchin; Coverage issues for Transcutaneous Electronic Stimulation for chronic lower back pain. Issue relating to MDUFA fees and sequestration.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
WHITNEY GARDINER —
JOHN CHRISTOPHER KALAVRITINOS —
TIMOTHY MCBRIDE —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); SENATE

Bills named: S. 17 (112th), H.R. 3209 (112th), H.R. 3208 (112th), H.R. 3230 (112th), S. 1995 (112th), H.R. 3214 (112th), H.R. 3206 (112th), H.R. 3211 (112th), S. 1700 (112th), S. 1943 (112th), S. 1865 (112th), H.R. 3204 (112th), H.R. 436 (112th), S. 262 (112th), S. 1972 (112th), H.R. 3203 (112th), H.R. 488 (112th), H.R. 734 (112th), H.R. 3205 (112th), S. 99 (112th), S. 3187 (112th)

Pharmacy PHA

Issues involving controlled substance and pain and addiction drugs generally; H.R. 2119: Ryan Creedon Act of 2011To amend the Controlled Substances Act to require practitioners to obtain particular training or special certification, approved by the Attorney General, on addiction to and abuse of controlled substances and appropriate and safe use of controlled substances in schedule II, III, IV, or V, and for other purposes; Issues related to acetaminophen.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
WHITNEY GARDINER —
JOHN CHRISTOPHER KALAVRITINOS —
TIMOTHY MCBRIDE —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE

Bills named: H.R. 2119 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.